1 PRODUCT NAME
PRO-BANTHINE propantheline bromide 15 mg tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
PRO-BANTHINE tablets contain 15 mg of propantheline bromide.

Propantheline bromide powder is a quaternary ammonium compound (2-diisopropylaminoethyl xanthen-9-carboxylate methobromide) with a melting point 157° to 162°C. At relative humidities of more than 50% it is hygroscopic and it is deliquescent above about 90%.

Propantheline bromide is a white or yellowish-white odourless powder with a very bitter taste. It is very soluble in water, alcohol and chloroform, however, is insoluble in ether.

Propantheline bromide has the molecular formula C_{23}H_{30}BrNO_{3} (CAS-50-34-0) with a molecular weight of 448.40.

Excipients with known effect: Contains soya bean and sugars as lactose.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM
PRO-BANTHINE tablets: A round, pale orange, film-coated tablet, plain on both sides

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
PRO-BANTHINE is indicated as an adjunctive therapy in the treatment of peptic ulcer (gastric and duodenal) and for the relief of the symptoms of gastritis. PRO-BANTHINE is also indicated for the symptomatic treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis, acute enterocolitis, nervous diarrhoea and functional gastrointestinal disorders). Other indications include renal colic, hyperhidrosis, as adjunctive therapy in ulcerative colitis, diverticulitis, cholecystitis and pancreatitis and for certain gastrointestinal diagnostic procedure.

4.2 Dose and method of administration
ADULTS
In peptic ulcer cases, one tablet three times a day, 30 minutes before each meal, and two at bedtime is usual (75 mg daily). There is considerable variation of individual needs and the dosage may be raised until dryness of the mouth occurs. A dose slightly lower than this amount is optimal. The maximum daily dosage should not exceed 120 mg.

For contrast radiology two tablets (30 mg) should be given 45 minutes before radiology.

For other indications the dose is one or two tablets (15 mg to 30 mg) four times daily.
4.3 Contraindications
The medicine is contraindicated in patients with:

- Hypersensitivity to propantheline bromide or other anticholinergic agents, or any of the ingredients in PRO-BANTHINE tablets (see Section 6.1 LIST OF EXCIPIENTS)
- Tachycardia secondary to cardiac insufficiency or thyrotoxicosis
- Glaucoma, since mydriasis is to be avoided
- Obstructive disease of the gastrointestinal tract (pyloroduodenal stenosis, achalasia, paralytic ileus, etc)
- Obstructive uropathy (prostatism)
- Intestinal atony of elderly or debilitated patients
- Toxic megacolon complicating ulcerative colitis
- Hiatal hernia associated with reflux oesophagitis
- Unstable cardiovascular adjustment in acute haemorrhage
- Myasthenia gravis
- Prostatic enlargement

4.4 Special warnings and precautions for use
Potential risks or benefits should be carefully considered before using the product.

PRO-BANTHINE should be used with caution in patients with severe cardiac disease in whom even a slight increase in heart rate is undesirable.

PRO-BANTHINE should be used with caution in the elderly and in all patients with autonomic neuropathy, hepatic or renal disease, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, mitral stenosis or hypertension.

Propantheline bromide should be used with caution in patients with chronic lung disease, as inspissation and formation of bronchial plugs may occur, due to the reduction in bronchial secretion.

In some patients, especially those with ileostomy or colostomy, diarrhoea may be a symptom of incomplete intestinal obstruction. Propantheline bromide therapy should be avoided in such patients.

Caution is required in patients with ulcerative colitis, since in these patients propantheline bromide may suppress intestinal motility to the point of producing paralytic ileus, thus precipitating or aggravating toxic megacolon.

Caution is also required in patients with known or suspected gastrointestinal infections such as Clostridium difficile-associated diarrhoea and colitis, gastrointestinal reflux disease, acute myocardial infarction, cardiac insufficiency and Pyrexia. Gastrointestinal motility may decrease, so continuance of causative toxins and organisms occur, therefore prolonging the infection symptoms.

Caution is required for those patients with fever or who may be exposed to elevated environmental temperatures, as there may be an increase in the risk of hyperthermia occurring. Fever and possibly heat stroke may occur due to anhidrosis.

Propantheline bromide should be used with caution in patients with Down’s syndrome.

Patients with rare hereditary problems of galactose intolerance or total lactase deficiency should not take this medicine.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Use in hepatic impairment

Propantheline bromide should be used with caution in all patients with hepatic disease.

Use in renal impairment

Propantheline bromide should be used with caution in all patients with renal disease.

Use in Children

Safety and efficacy of propantheline bromide in children have not been established.

Use in Elderly

Caution should also be exercised in elderly patients because of the possibility of inducing urinary retention. Urinary retention may be avoided if these patients are advised to micturate at the time of taking medication. Caution should also be exercised in elderly patients due to the danger of precipitating undiagnosed glaucoma.

4.5 Interaction with other medicines and other forms of interaction

Antacids or Absorbent Antidiarrhoeals: May reduce the absorption of propantheline bromide, therefore resulting in a reduction of its therapeutic effectiveness. Therefore, take two to three hours apart from doses of propantheline bromide.

Anticholinergics: May delay absorption of other medication given concomitantly.

Antimyasthenics: Concurrently used with propantheline bromide may further reduce intestinal motility.

Increased intra-ocular pressure may result from concurrent administration of anticholinergics and corticosteroids.

Cisapride: Concurrent use of propantheline bromide with cisapride is likely to counteract gastrointestinal motility normally induced by cisapride.

Digoxin tablets concurrently used with propantheline bromide may assist absorption and lead to elevated serum digoxin levels.

Haloperidol concurrently used with propantheline bromide may decrease the effectiveness of haloperidol as an antipsychotic agent. Increased risk of antimuscarinic side effects when antimuscarinics are given with clozapine.

Ketoconazole: Anticholinergics may decrease gastric acid output and/or increase gastrointestinal pH, possibly resulting in reduction of ketoconazole absorption during concurrent use with anticholinergics. Therefore, take propantheline bromide at least two hours after ketoconazole.

Levodopa: Concurrent administration of anticholinergics and levodopa may decrease the extent of absorption of levodopa in the small intestine by causing increased metabolism of levodopa in the stomach. If propantheline bromide is discontinued without a concomitant reduction in levodopa dosage, toxicity may result from the increased absorption of levodopa. Increased risk of antimuscarinic side effects when antimuscarinics are given with amantadine.
Metoclopramide: Concurrently used with propantheline bromide may cause propantheline bromide to antagonise the gastrointestinal motility effects of metoclopramide.

Opioid (narcotic) Analgesics: Concurrently used with propantheline bromide may cause an increase in the risk of severe constipation. This may lead to urinary retention or paralytic ileus occurring.

Analgesics: Increased risk of antimuscarinic side effects when antimuscarinics are given with nefopam. The absorption of paracetamol has been reported to be reduced and retarded.

Propantheline bromide may also potent phenothiazines.

Potassium chloride, especially wax-matrix preparations: Concurrent use with propantheline bromide may increase severity of potassium chloride-induced gastrointestinal lesions.

Urinary alkalisers (e.g. antacids, carbonic anhydrase inhibitors and sodium bicarbonate): May cause a delay in urinary excretion, therefore potentiating propantheline bromide's therapeutic and/or side effects. Memantine: Effects of antimuscarinics possibly enhanced by memantine.

Nitrates: antimuscarinics possibly reduce effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth).

Domperidone: antimuscarinics antagonise effects of domperidone on gastrointestinal activity.

Anti-infectives: the absorption of nitrofurantoin has been reported to be enhanced.

Parasympathomimetics: antimuscarinics antagonise effects of parasympathomimetics.

Excessive cholinergic blockage may occur if propantheline bromide is given concomitantly with antihistamines; Type 1 antiarrhythmic agents (e.g. disopyramide, procainamide or quinidine); synthetic and semisynthetic anticholinergic agents; Belladonna alkaloids; narcotic analgesics e.g. pethidine; phenothiazines, tricyclic antidepressants, MAOIs or tricyclics, synthetic and semi-synthetic antimuscarinic agents or other psychoactive agents.

4.6 Fertility, pregnancy and lactation

Effects on Fertility
There is no information available on the possible effects of propantheline bromide on human fertility.

Use In Pregnancy
Safe use of propantheline bromide in pregnancy has not been established. Therefore, the use of this medicine in women of child-bearing potential requires that the benefits be weighed against its possible hazards to mother and foetus.

Cohort data on parasympatholytics indicate a possible association with minor malformations. In view of this, propantheline bromide should not be administered in pregnancy unless considered essential.

Use In Lactation
Information regarding the secretion of propantheline bromide in breast milk is limited to uncontrolled data derived from marketing experience. Such experience does not suggest that significant quantities of propantheline bromide are secreted in breast milk, since propantheline bromide is incompletely absorbed from the gastrointestinal tract and has poor lipid solubility. Because many agents are excreted in human milk, caution should be exercised when propantheline bromide is administered to a breast-feeding woman. Suppression of lactation may occur with anticholinergic agents.
4.7 Effects on ability to drive and use machines
Propantheline bromide may produce drowsiness or blurred vision. Patients should be cautioned regarding operating machinery or motor vehicles during treatment with this medicine.

4.8 Undesirable effects
The adverse effects of propantheline bromide are usually dose-related and are usually reversible when the therapy is discontinued.

The following adverse effects have been reported:

**Cardiovascular**
Palpitations, arrhythmias, bradycardia followed by tachycardia.

**Neurological**
Insomnia, drowsiness, dizziness, nervousness, headache, mental confusion, weakness.

**Dermatological and Hypersensitivity Reactions**
Anaphylaxis, urticaria, rashes, allergic dermatitis.

**Gastrointestinal**
Bloating, nausea, vomiting, constipation.

**Genitourinary**
Urinary hesitancy and retention, impotence.

**Respiratory**
Reduced bronchial secretions.

**Ophthalmic**
Blurred vision, mydriasis, cycloplegia, increased ocular tension, dilation of the pupils with loss of accommodation and sensitivity to light.

**Other Effects**
Xerostomia (dry mouth), decreased salivary secretions, decreased sweating (anhidrosis), heat stroke, flushing, dryness of the skin, dryness of the mouth, thirst, difficulty in swallowing and talking, loss of the sense of taste, suppression of lactation.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).
4.9 Overdose

Symptoms
The symptoms of overdosage with propantheline bromide progress from an intensification of the usual side effects (from nausea and vomiting) to CNS disturbances (from restlessness and excitement to psychotic behaviour), hyperthermia, circulatory changes, (flushing, fall in blood pressure, circulatory failure), respiratory failure, paralysis and coma. With overdosage, a curare-like action may occur i.e. neuromuscular blockade leading to muscular weakness and possible paralysis. Additionally, a rash may appear on the face or the upper trunk of the body. At high doses, propantheline bromide has some ganglion-blocking activity; therefore postural hypotension and impotency may occur.

Treatment
Treatment of overdosage of propantheline bromide consists of symptomatic and supportive therapy. An aqueous slurry of activated charcoal may be administered to decrease medicine adsorption. For the reversal of severe overdosage symptoms, an intravenous injection of physostigmine 0.5 to 2 mg is administered, and repeated as necessary up to a total of 5 mg. Fever may be treated symptomatically (alcohol sponging, ice packs).

Excitement of a degree which demands attention may be managed with sodium thiopentone 2% solution given slowly intravenously or diazepam, 5 to 10 mg intravenously or 10 mg intramuscularly. In the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns. Adequate hydration is also required.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Propantheline bromide is an anticholinergic agent which inhibits neural impulses at the effector sites of the parasympathetic nervous system and at the ganglia of the sympathetic and parasympathetic nervous system with peripheral effects similar to atropine. Propantheline bromide does not readily cross the blood brain barrier thus avoiding the central effects seen with atropine. Propantheline bromide reduces gastric acid secretion and inhibits gastrointestinal motility and has spasmolytic properties. Other secretions including pancreatic juice, sweat and saliva are reduced.

5.2 Pharmacokinetic properties
After oral administration to man, propantheline bromide is extensively metabolized primarily by hydrolysis to the inactive materials xanthene-9-carboxylic acid and (2-hydroxyethyl) diisopropylmethylammonium bromide, approximately half of which occurs in the gastrointestinal tract prior to its absorption. Food appears to substantially decrease the extent of absorption following oral administration. After a single 15 mg oral dose of carbon-14 labelled medicine given to a healthy man, 390 ng/mL peak plasma concentration of total -14C material is attained at 6 hours.
Single oral doses of 15, 30, 45, 60, 75, 90 mg of propantheline bromide tablets were administered to each of 6 subjects and were rapidly absorbed. The absorption half-life of propantheline bromide was 8-30 minutes, and half-life of elimination between 1.3 and 2.1 hours.

Average peak plasma concentrations of propantheline after the 15, 30, 45, 60, 75 and 90 mg doses were 6, 29, 81, 62, 148 and 146 ng/mL respectively, and were attained within 3 hours of oral dosing. Similarly, the average amount of unmetabolized propantheline excreted in the urine was 0.70, 1.08, 1.59, 1.85, 2.42 and 3.06 ng/mL respectively.

Unmetabolized medicine represents only a small proportion of the total $^{14}$C materials. The plasma half-life of the total $^{14}$C material is about 9 hours and approximately 70 per cent of the dose is excreted in the urine, mostly as metabolite. The urinary excretion of the intact propantheline is about 5 per cent after oral administration and about 20 per cent after intravenous administration.

The distribution of propantheline bromide in the body has not been determined. It appears that it does not readily penetrate the CNS and eye, due to complete ionisation and poor lipid solubility.

5.3 Preclinical safety data
Genotoxicity
Animal studies to determine the mutagenic potential of propantheline bromide have not been established.

Carcinogenicity
Animal studies to determine the carcinogenic potential of propantheline bromide have not been established.

6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
- Lactose monohydrate
- Purified talc
- Maize starch
- Magnesium stearate
- OPADRY II complete film coating system 85G63218 ORANGE.

Refer to Section 2 - Qualitative and quantitative composition.

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
24 months from date of manufacture.
NEW ZEALAND DATA SHEET

6.4 Special precautions for storage
Store below 25°C.
Keep this medication out of the reach of children.

6.5 Nature and contents of container
PRO-BANTHINE tablets are supplied in HDPE bottles (with child-resistant closures) containing 100 tablets.

6.6 Special precautions for disposal
Any unused medicine or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE
Prescription Medicine

8 SPONSOR
Exclusive New Zealand distributors:
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
58 Richard Pearse Drive
Airport Oaks
Mangere
AUCKLAND

9 DATE OF FIRST APPROVAL
31/12/1969

10 DATE OF REVISION OF THE TEXT
15 July 2022
## SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Minor editorial changes</td>
</tr>
</tbody>
</table>
| 4.3, 4.4, 4.5, 4.6 and 4.8 | Additional contraindications, Warnings and precautions, Interactions with other medicines, adverse effects added.  
Additional safety related info added in Use in pregnancy. |